Latest News
News Functions
Additional Functions
5 June 2017
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs Inc. to Commercialize Envarsus XR(r) in Canada
10 July 2015
Veloxis Pharmaceuticals A/S
Veloxis Announces U.S. FDA Approval of Envarsus® XR for Treatment of Kidney Transplant Patients
24 June 2015
Veloxis Pharmaceuticals A/S
Envarsus® XR Demonstrates Differentiated Pharmacokinetic Profile Compared to Twice-Daily Prograf® or Once-Daily Astagraf XL® in Stable Kidney Transplant Patients
12 June 2015
Veloxis Pharmaceuticals A/S
U.S. District Court Rules in Veloxis Litigation
3 June 2015
Veloxis Pharmaceuticals A/S
Warrant Programme – Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants
20 May 2015
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals announces financial results for the first three months of 2015
12 May 2015
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for the first Quarter 2015 – results from 1 January to 31 March, 2015
4 May 2015
Veloxis Pharmaceuticals A/S
Envarsus® XR Demonstrates Improved Pharmacokinetic Profile in African-American Transplant Recipients
10 April 2015
Veloxis Pharmaceuticals A/S
Warrant Programme – New Articles of Association
27 March 2015
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S establishes new Warrant Programme
Veloxis Pharmaceuticals A/S
Warrant Programme – Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants
26 March 2015
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S – Passing of Annual General Meeting
4 March 2015
Veloxis Pharmaceuticals A/S
Notice to Convene Annual General Meeting
3 March 2015
Veloxis Pharmaceuticals A/S
Warrant Programme – New Articles of Association
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S establishes new Warrant Programme
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals publishes Annual Report 2014
24 February 2015
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Annual report 2014 – results from 1 January to 31 December, 2014
21 January 2015
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals Announces Updated Financial Calendar for 2015
14 January 2015
Veloxis Pharmaceuticals A/S
U.S. District Court Sets Briefing Schedule in Veloxis Litigation
13 January 2015
Veloxis Pharmaceuticals A/S
Veloxis Confirms Receipt of U.S. Food and Drug Administration Decision
19 December 2014
Veloxis Pharmaceuticals A/S
Veloxis Comments on U.S. District Court Order
16 December 2014
Veloxis Pharmaceuticals A/S
Veloxis announces that it has filed an action against the Food and Drug Administration, seeking an order requiring FDA to grant final approval to Envarsus® XR.
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals Announces Financial Calendar for 2015
17 November 2014
Veloxis Pharmaceuticals A/S
Veloxis Announces Publication of Phase III Study of Once Daily Envarsus® XR Demonstrating Non-Inferiority vs. Twice-Daily Tacrolimus in De Novo Kidney Transplant Patients
Veloxis Pharmaceuticals A/S
Warrant Programme – New Articles of Association
12 November 2014
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S establishes new Warrant Programme
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals announces financial results for the first nine months of 2014 and improves the full year outlook
7 November 2014
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S to Host Conference Call Announcing Interim Report for third Quarter 2014 – results from 1 January to 30 September, 2014
31 October 2014
Veloxis Pharmaceuticals A/S
Veloxis Pharmaceuticals A/S to Host Conference Call discussing the FDA tentative approval of Envarsus® XR
Veloxis Pharmaceuticals A/S
Veloxis announces tentative approval of Envarsus® XR